Moderate To Severe Crohn S Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for moderate to severe crohn s disease. 9 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
9
Active US patents
54/100
Avg vulnerability
—
Annual revenue covered

Originators in Moderate To Severe Crohn S Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating moderate to severe crohn s disease. Each bar = one year. Y-axis scaled to peak year (7 patents).

1
29
1
30
7
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Velsipity
Etrasimod Arginine
 Pfizer Inc. 9 54 — 2029-07-22

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9126932 Velsipity method of use 76 2029-07-22
12156866 Velsipity method of use 75 2036-01-06
12377071 Velsipity method of use 75 2036-01-06
11884626 Velsipity method of use 75 2036-06-21
11007175 Velsipity method of use 70 2036-01-06
10676435 Velsipity method of use 70 2036-06-21
8580841 Velsipity composition of matter 18 2030-03-05
11091435 Velsipity composition of matter 12 2036-06-21
10301262 Velsipity composition of matter 12 2036-06-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11091435 Velsipity composition of matter 12 2036-06-21
10301262 Velsipity composition of matter 12 2036-06-21
8580841 Velsipity composition of matter 18 2030-03-05
10676435 Velsipity method of use 70 2036-06-21
11007175 Velsipity method of use 70 2036-01-06
11884626 Velsipity method of use 75 2036-06-21
12156866 Velsipity method of use 75 2036-01-06
12377071 Velsipity method of use 75 2036-01-06
9126932 Velsipity method of use 76 2029-07-22

Related